Drugs Made In America Acquisition II entered into an unsecured convertible bridge note to support near-term transaction costs. The $150,000 note bears no interest, matures in nine months, and may convert at the investor’s option into shares of the post-combination company at a 35% discount upon completion of the business combination. Proceeds will fund accounting, audit and other combination-related expenses. The bridge note is the first tranche toward a contemplated $1.4 million convertible notes financing under a letter of intent.
Agreement details:
- Agreement type: Unsecured zero-interest convertible bridge promissory note
- Counterparty: Alpha Multi Family Office
- Signed / Effective: Mar 11 2026 / same
- Duration / Termination: 9 months
- Reason: Fund accounting, audit and other business combination expenses
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.